Yongan Pharmaceutical: 2024 net profit of 61.76 million yuan, turning losses into profits compared to the same period last year, plans to distribute 1 yuan per 10 shares.

On April 9, Yongan Pharmaceutical announced that its operating income in 2024 will be 839 million yuan, a year-on-year decrease of 13.78%. The net profit attributable to shareholders of listed companies was 61.766 million yuan, compared with a net loss of 12.313 million yuan in the same period last year. Basic earnings per share was 0.2107 yuan/share. Based on the existing total share capital of 295 million shares after deducting the shares in the special securities account for repurchase (as of the disclosure date, the company has repurchased a total of 5,537,350 shares of the company) of the share capital of 289 million shares, a cash dividend of 1 yuan (tax included) will be distributed to all shareholders for every 10 shares, and 0 bonus shares (tax included) will be given, and the share capital will not be increased by provident fund.